article thumbnail

Access solutions: the missing link that prevents biopharma innovation from reaching patients

pharmaphorum

However, most models are based on an old-fashioned and expensive call centre-based approach that fails to meet the needs of patients and healthcare providers (HCPs) as consumers. The post Access solutions: the missing link that prevents biopharma innovation from reaching patients appeared first on.

article thumbnail

Veradigm® Digital Health Media Works to Message the Right Physicians at the Right Time

PM360

Though 80% of healthcare providers (HCPs) identified as “rep-accessible” in 2008 (that is, willing to meet with over 70% of the sales reps who try to approach them), that number had decreased to 44% in 2017. No biopharma or device advertisements appear during the prescribing workflow.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Accelerating HCP engagement in Singapore using customer reference data

Veeva

Get continuous, automatic data updates to improve sales rep productivity and drive intelligent engagement with healthcare providers. Quickly confirm specialty data, prescriptive authority, and sample eligibility to ensure compliance with regulations and privacy laws. Streamline compliance. Improve planning.

Sales 52
article thumbnail

How retailers and “payviders” are disrupting U.S. healthcare in 2024

Clarivate

Since buying the chain, Amazon has made strategic expansions of its brick-and-mortar locations ( Connecticut , San Francisco , and Milwaukee ), increased IDN partnerships for specialty referrals to 18, and introduced healthcare-focused subscription services, including One Medical and RxPass.

Retail 52
article thumbnail

What Pear Therapeutics’ Bankruptcy Has Left the DTX Industry to Ponder

MedCity News

Bringing the very first prescription digital therapeutic (PDT) to market in 2017, Pear Therapeutics went above and beyond to follow suggested regulatory guidelines, obtained Food & Drug Administration (FDA) clearance, and provided solid clinical study evidence. Photo: Bulat Silvia, Getty Images

article thumbnail

Bringing Therapies from Bench to Bedside: Navigating Challenges in the Last Mile

Clarify Health

Any misstep in terms of pricing, reimbursement, or marketing could mean delays in providing therapies to the patients who need them most. Customer conversion and product uptake have largely depended upon live interactions between treating physicians and biopharma representatives (e.g., sales, medical science liaisons, etc.).

article thumbnail

Understanding a rare disease through the lens of real world and prevalence data

Clarivate

Our analysis included prescription trends for antibiotics, steroids, vitamins and ophthalmic-intraocular pressure reducing agents (prostaglandin analogs and alpha-adrenergic agonists) from 2018 to 2021. Learn more about the Clarivate real world data offering here.